Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | YES1 | P07947 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933030 | 0.95 | BRAF (0.46) | BRAFPIM3RAF1EGFRKDR | |
| SCHEMBL2927174 | 0.92 | BRAF (0.46) | BRAFPIM3RAF1KDRPIM1 | |
| SCHEMBL2928817 | 0.88 | KDR (0.38) | BRAFPIM3KDRPIM1FYN | |
| SCHEMBL2930097 | 0.80 | BRAF (0.37) | BRAFPIM3RAF1KDRPIM1 | |
| Trifluoroacetic Acid SCHEMBL2933649 | 0.80 | PIM3 (0.52) | BRAFPIM3RAF1KDRFYN | |
| Trifluoroacetic Acid SCHEMBL2933025 | 0.79 | FYN (0.53) | BRAFPIM3RAF1KDRPIM1 | |
| SCHEMBL14269639 | 0.78 | PIM3 (0.55) | BRAFPIM3RAF1KDRFYN | |
| SCHEMBL13515278 | 0.76 | FYN (0.59) | BRAFPIM3RAF1KDRPIM1 | |
| SCHEMBL2928592 | 0.74 | PIM3 (0.71) | BRAFPIM3RAF1 | |
| SCHEMBL2933651 | 0.74 | PIM3 (0.52) | BRAFPIM3RAF1KDRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | BRAF 524/4885PIM3 2131/4885RAF1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.